In the Claims:

1-8. (canceled)

9. (previously presented) A method for detecting colon or prostate cancer, comprising:

a) providing a sample from a subject suspected of having cancer; and

b) detecting the presence or absence of HIP1 in said sample with a reagent configured to detect HIP1 having the nucleic acid sequence of SEQ ID NO:1; wherein the presence of HIP1 in said sample is indicative of colon or prostate cancer in said subject.

10-11. (canceled)

12. (original) The method of Claim 9, wherein said sample is a tumor sample.

13. (original) The method of Claim 9, wherein said sample is a tissue sample.

14. (original) The method of Claim 13, wherein said tissue sample is selected from the group consisting of prostate tissue and colon tissue.

15. (original) The method of Claim 9, wherein said sample is selected from the group consisting of serum, plasma, blood, and urine.

16. (previously presented) The method of Claim 9, wherein said detecting HIP1 comprises detecting the presence of HIP1 mRNA.

17. (original) The method of Claim 16, wherein said detecting the presence of HIP1 mRNA comprises exposing said HIP1 mRNA to a nucleic acid probe complementary to at least a portion of said HIP1 mRNA.

18. (original) The method of Claim 17, wherein said detecting the presence of HIP1 mRNA comprises a detection assay selected from the group consisting of a Northern blot, in situ hybridization, reverse-transcriptase polymerase chain reaction, and microarray analysis.

19-22. (canceled)

23. (original) The method of Claim 9, wherein said method further comprises step c) providing a prognosis to said subject.

24. (currently amended) A method for characterizing prostate cancer in a subject, comprising:

a) providing a sample from a subject, wherein said subject has been diagnosed with ~~colon or~~ prostate cancer; and

b) characterizing said sample by detecting the presence or absence of HIP1 in said sample with a reagent configured to detect a HIP1 nucleic acid having the nucleic acid sequence of SEQ ID NO:1, wherein said presence or absence of HIP1 in said sample is indicative of one or more of properties of said cancer selected from the group consisting of risk of prostate specific antigen failure, risk of said cancer metastasizing, risk of said cancer recurring, and stage of said cancer.

25. (previously presented) The method of Claim 24, wherein said sample is tumor tissue.

26. (previously presented) The method of Claim 24, wherein said sample is biopsy tissue.

27. (original) The method of Claim 24, wherein said detecting HIP1 comprises detecting the presence of HIP1 mRNA.

28. (original) The method of Claim 27, wherein said detecting the presence of HIP1 mRNA comprises exposing said HIP1 mRNA to a nucleic acid probe complementary to at least a portion of said HIP1 mRNA.

29. (original) The method of Claim 28, wherein said detecting the presence of HIP1 mRNA comprises a detection assay selected from the group consisting of a Northern blot, in situ hybridization, reverse-transcriptase polymerase chain reaction, and microarray analysis.

30-33. (canceled)

34-35. (canceled)

36. (previously presented) The method of Claim 24, wherein said stage of said cancer is selected from the group consisting of high-grade prostatic intraepithelial neoplasia, benign prostatic hyperplasia, prostate carcinoma, and metastatic prostate carcinoma.

37-38. (canceled)

39-83. (canceled)

84. (withdrawn) The method of Claim 9, wherein said reagent is configured to detect an ENTH deletion mutant of said HIP1.

85. (withdrawn) The method of Claim 9, wherein said reagent is configured to detect SEQ ID NO:4.

86. (withdrawn) The method of Claim 9, wherein said reagent is configured to detect an ENTH domain of said HIP1.

87. (previously presented) The method of Claim 24, wherein said property of said cancer is said risk of prostate specific antigen failure.

88. (previously presented) The method of Claim 24, wherein said property of said cancer is said risk of said cancer metastasizing.

89. (previously presented) The method of claim 24, wherein said property of said cancer is said risk of said cancer recurring.

90. (previously presented) The method of claim 24, wherein said property of said cancer is said stage of said cancer.

91. (withdrawn) The method of Claim 24, wherein said reagent is configured to detect an ENTH deletion mutant of said HIP1.

92. (withdrawn) The method of Claim 24, wherein said reagent is configured to detect SEQ ID NO:4.

93. (withdrawn) The method of Claim 24, wherein said reagent is configured to detect an ENTH domain of said HIP1.